(AQST) Aquestive Therapeutics, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(AQST) Aquestive Therapeutics, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Aquestive Therapeutics, Inc. 4P's Marketing Mix Analysis explains the company’s product offerings, pricing strategy, distribution channels, and promotion tactics in a concise, actionable format; the page shows a real preview/sample of the report so you can judge style and content before buying—purchase the full version to receive the complete ready-to-use analysis.
Product
4 commercial brands
Aquestive Therapeutics, Inc. markets 4 brands: Sympazan, Suboxone, Zuplenz, and Azstarys. They cover neurology, opioid dependence, oncology supportive care, and ADHD, and each uses a differentiated delivery format, which supports a prescription-focused mix. In 2025, this portfolio still anchored the Company Name’s commercial base.
5 pipeline candidates
Aquestive Therapeutics, Inc. disclosed five pipeline candidates: Libervant for seizures, Exservan for ALS, AQST-108 for systemic epinephrine use, AQST-305 for acromegaly, and AQST-109 for severe allergic reactions. This pipeline broadens the mix beyond marketed products and targets large unmet-need markets, including seizure rescue and emergency allergy care.
Oral soluble film platform
Aquestive Therapeutics, Inc. is built on oral soluble film delivery, a strip that dissolves without water and can help in both acute and chronic use. The platform spans multiple branded assets, including Sympazan for Lennox-Gastaut syndrome and Libervant for seizure rescue, showing how one dosage form can support different therapies. Its 2025 focus on Anaphylm, an epinephrine oral film candidate, shows the platform’s push into a large rescue-care market.
Buccal and sublingual dosing
Buccal and sublingual dosing is core to Aquestive Therapeutics, Inc.'s drug-delivery platform, supporting non-pill, rapid-absorption products like Libervant, Suboxone, and KYNMOBI work. Libervant's FDA approval in 2024 for seizure clusters shows the route can turn hard-to-take medicines into fast, patient-friendly options.
- Fast, non-pill delivery
- Used across key assets
- Supports seizure and CNS care
KYNMOBI development role
Aquestive Therapeutics helped develop KYNMOBI, a sublingual apomorphine film for episodic OFF periods in Parkinson’s disease. As of 2025, it remains the first and only sublingual apomorphine film in the U.S., showing Aquestive’s track record in specialty neurology and fast-use drug delivery.
- First-and-only sublingual apomorphine film
- Targets episodic Parkinson’s OFF periods
- Shows specialty neurology expertise
- Uses non-oral, rapid-dissolve delivery
Aquestive’s Fast-Acting Drug Portfolio: What Investors Should Know
Aquestive Therapeutics, Inc.'s Product mix centers on oral soluble film and buccal delivery, with Sympazan, Suboxone, Zuplenz, and Azstarys in market and Libervant approved in 2024 for seizure clusters. The platform supports fast, non-pill use across neurology, opioid dependence, oncology support, and ADHD.
| Key Product | Status | Use |
|---|---|---|
| Sympazan | Marketed | Lennox-Gastaut syndrome |
| Libervant | Approved 2024 | Seizure clusters |
| KYNMOBI | Marketed | Parkinson’s OFF periods |
What is included in the product
Detailed Word Document
A concise, company-specific breakdown of Aquestive Therapeutics, Inc.’s Product, Price, Place, and Promotion strategy.
Editable Excel File
Turns Aquestive Therapeutics’ 4Ps into a quick pain-point snapshot for fast strategy review and clear team alignment.
Reference Sources
Lists primary, reputable sources that link each key claim about Aquestive Therapeutics to traceable industry reports, datasets, and benchmarks to speed due diligence and verify assumptions.
Place
Warren, New Jersey headquarters
આక్వెస్టివ్ થેરાપ્યુટિક્સ is headquartered in Warren, New Jersey, and this site is its main U.S. base. The Warren headquarters anchors corporate, research, and commercial work in one place, so it supports day-to-day decision-making and product execution. For a 2025–2026 operating view, that central hub matters because it ties together 3 core functions under one roof.
U.S. and international markets
Aquestive Therapeutics, Inc. sells across the U.S. and international markets, giving it a multi-region commercial footprint instead of a single-country model. Its 2025 filings show the business depends on both domestic product sales and ex-U.S. partner markets, which spreads commercial risk and widens reach. That matters in a small-cap pharma model because growth can come from more than one geography at the same time.
Prescription pharmacy access
Aquestive Therapeutics, Inc. sells prescription-only medicines, so access runs through licensed prescribers and pharmacy channels, not direct retail. Patients get the drug only after a prescription is written, which adds a gate but also supports tighter clinical oversight and payer review. This model fits its Rx portfolio, including SYMPAZAN, a clobazam oral film approved for epilepsy.
Specialty and acute-care settings
Specialty and acute-care settings fit Aquestive Therapeutics, Inc. because its products target epilepsy, opioid use disorder, ALS, acromegaly, and severe allergic reactions, which are usually managed by specialists and high-touch pharmacy channels.
That channel mix matters: epilepsy affects about 3.4 million people in the U.S., and severe food allergies affect about 33 million Americans, so access often runs through neurology, allergy, and specialty pharmacy networks.
- Specialty care supports complex use cases and channel access.
- High-acuity products rely on specialty prescribers and pharmacies.
Partner-led reach
Partner-led reach lets Aquestive Therapeutics, Inc. extend access beyond its own sales channels, which matters for a small pharma platform with limited direct commercial scale. Partnered assets can speed geographic rollout, share launch costs, and widen payer and prescriber access without building a full field force. In 2025, that model is still key for converting R&D assets into broader market uptake.
- Extends reach beyond direct channels
- Shares launch and access costs
- Fits a small platform company
Estosive Therapeutics: Warren HQ Powers Specialty Rx Reach
Place is centered in Warren, New Jersey, where Aquestive Therapeutics, Inc. runs corporate, research, and commercial work from one U.S. hub. Its reach is mostly prescription-based through specialty pharmacies and prescribers, with partner-led access outside the U.S. That setup fits a small pharma model serving epilepsy, allergy, and other specialist markets.
| Place factor | 2025-2026 view |
|---|---|
| HQ | Warren, New Jersey |
| Channel | Rx specialty pharmacy |
| Reach | U.S. plus partners abroad |
Get Your Copy
Aquestive Therapeutics, Inc. Reference Sources
The preview shown here is the actual document you’ll receive instantly after purchase—no surprises.
This Marketing Mix covers Aquestive Therapeutics’ Product, Price, Place, and Promotion with actionable insights and competitor context tailored for decision-makers.
You’re viewing the exact editable, ready-to-use analysis included with your purchase, suitable for presentations or strategy work.
Promotion
HCP-focused product education
HCP-focused education is the core of Aquestive Therapeutics, Inc.’s promotion, aimed at prescribers of specialty drugs. It links the delivery platform to 8 labeled use areas: epilepsy, opioid dependence, nausea and vomiting, ADHD, ALS, Parkinson’s disease, acromegaly, and anaphylaxis. The goal is simple: build awareness of the platform and drive correct use in practice.
Pipeline milestone updates
Aquestive Therapeutics, Inc. promotes pipeline progress by issuing clear milestone updates on its clinical, regulatory, and commercial assets. In 2024, the FDA accepted the Anaphylm NDA and set a February 27, 2025 PDUFA date, giving investors and physicians a fixed review timeline. These updates signal development momentum and keep the market focused on each step toward approval.
Regulatory approval communications
For Aquestive Therapeutics, FDA news is a key promotion tool: the 2024 approval of Libervant for seizure clusters in children ages 2 to 5 gave the Company a hard proof point for product availability and use. Label updates and review milestones also help build trust in its oral-film platform, since regulatory wins are a strong signal of safety, efficacy, and manufacturing quality. These events can sharpen physician and payer awareness fast, especially when they come from the FDA, the most watched drug regulator in the U.S.
Partner commercialization support
Partner commercialization support lets Aquestive Therapeutics, Inc. extend promotion through licensees and co-commercial partners, so specialty products can reach more prescribers without building a full field force. This matters most for niche assets, where partner sales teams and payer access can cut launch cost and speed uptake.
- Broader reach, lower fixed SG&A
- Faster access via partner field teams
- Best fit for specialty pharma assets
Investor relations and SEC disclosure
In 2025, Aquestive Therapeutics used 10-K, 10-Q, earnings materials, and investor decks to explain product sales, pipeline progress, and strategy, giving capital markets a clear view of launch timing and regulatory milestones. This steady disclosure helps investors track revenue mix, R&D spend, and near-term catalysts.
Uses SEC filings and earnings updates
Shares sales, pipeline, and strategy
Builds awareness with investors
Aquestive Keeps Its Oral-Film Story in Front of Prescribers and Investors
Aquestive Therapeutics, Inc. promotes through HCP education, FDA milestone news, and partner-led commercialization. In 2025, its disclosure cadence around Anaphylm and Libervant kept the oral-film platform visible to prescribers and investors.
| Promotion lever | Latest proof point |
|---|---|
| FDA milestones | Anaphylm NDA accepted; PDUFA 2/27/2025 |
| Commercial proof | Libervant approved for ages 2–5 |
| Investor outreach | 10-K, 10-Q, earnings, decks |
Price
Prescription-only pricing
Aquestive Therapeutics, Inc. sells prescription drugs, so pricing sits inside the payer system, not on a retail shelf. Access depends on a prescriber order and pharmacy reimbursement, which makes list price only part of the real cost.
In 2025, Aquestive Therapeutics, Inc. reported $0.4 million in product sales and $44.1 million in total revenue, showing how tightly pricing is linked to coverage and uptake. That is why payer access and formulary placement matter more than consumer price tags.
Insurance and payer reimbursement
For Aquestive Therapeutics, Inc., patient cost is shaped by insurers, PBMs, and benefit design, so the same branded drug can face very different copays and prior-authorization hurdles. In U.S. branded prescriptions, list price rarely equals what the Company receives; net price is cut by rebates, discounts, and channel fees. Aquestive Therapeutics, Inc.'s realized price depends on coverage depth and contract terms.
Product-specific net pricing
Այս portfolio uses product-specific net pricing, not one uniform price, because each indication has a different patient base and market size. Specialty neurology and rare-disease drugs can support higher net economics than larger-volume products, and Aquestive Therapeutics, Inc. has said its pricing reflects each drug’s access and value profile across the 2025-2026 portfolio.
Contracted wholesale terms
For Aquestive Therapeutics, Inc., contracted wholesale terms mean pharmacies and distributors buy through negotiated commercial contracts, not sticker prices. That structure is standard in pharma and drives gross-to-net deductions, rebates, and chargebacks that reduce reported net revenue and shape revenue recognition under each contract.
- Negotiated contracts set net selling price.
- Gross-to-net deductions lower reported revenue.
- Revenue timing follows contract terms.
- Wholesale pricing is standard in pharma.
Competition and mix effects
Pricing at Aquestive Therapeutics, Inc. is shaped by generic competition and branded alternatives, so net price can swing hard by product. In U.S. pharma, generics often cut prices by 80% to 90% versus brands, while lower-volume, high-need therapies can still support stronger net pricing. That makes product mix a key driver of margin and cash flow.
- Generics pressure list and net prices.
- Branded drugs support better pricing.
- Rare-need products can price higher.
- Mix effects shape net revenue.
Net Price, Not List Price, Drives Aquestive’s Revenue
Aquestive Therapeutics, Inc. prices through payer contracts, so net price matters more than list price. In 2025, the Company reported $0.4 million of product sales and $44.1 million of total revenue, showing how access, rebates, and formulary terms shape realized price.
| Metric | 2025 |
|---|---|
| Product sales | $0.4 million |
| Total revenue | $44.1 million |
| Price driver | Payer access |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.